Edward Leicester Atkinson qualified at St Thomas's Hospital in 1906 and joined the Navy in 1908. He was a doctor and parasitologist on Captain Scott's Terra Nova expedition to the Antarctic and had to take charge of the expedition when Scott died on his return from the South Pole. After the expedition he went to China and discovered the cause of schistosomiasis, returning at the start of the First World War in which he served with distinction, winning a DSO and Albert Medal but also being severely injured. After the war he served in various naval posts and became the youngest Surgeon Captain in the Navy before being retired on health grounds in 1928. He died at sea the following year.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0967772014526131 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.
Lancet Diabetes Endocrinol
January 2025
Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. Electronic address:
Background: About half of patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF) have type 2 diabetes. In the STEP-HFpEF DM trial of adults with obesity-related HFpEF and type 2 diabetes, subcutaneous once weekly semaglutide 2·4 mg conferred improvements in heart failure-related symptoms and physical limitations, bodyweight, and other heart failure outcomes. We aimed to determine whether these effects of semaglutide differ according to baseline HbA.
View Article and Find Full Text PDFLong term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort study.
EClinicalMedicine
January 2025
Leicester Real World Evidence Unit, Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, LE5 4PW, UK.
Background: People with diabetes are at increased risk of hospitalisation, morbidity, and mortality following SARS-CoV-2 infection. Long-term outcomes for people with diabetes previously hospitalised with COVID-19 are, however, unknown. This study aimed to determine the longer-term physical and mental health effects of COVID-19 in people with and without diabetes.
View Article and Find Full Text PDFClinical validation of an artificial intelligence-based decision support system for diagnosis and risk stratification of heart failure (STRATIFYHF): a protocol for a prospective, multicentre longitudinal study.
BMJ Open
January 2025
Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK
Introduction: Heart failure (HF) is a complex clinical syndrome. Accurate risk stratification and early diagnosis of HF are challenging as its signs and symptoms are non-specific. We propose to address this global challenge by developing the STRATIFYHF artificial intelligence-driven decision support system (DSS), which uses novel analytical methods in determining the risk, diagnosis and prognosis of HF.
View Article and Find Full Text PDFBackground: Diarrhoeal diseases claim more than 1 million lives annually and are a leading cause of death in children younger than 5 years. Comprehensive global estimates of the diarrhoeal disease burden for specific age groups of children younger than 5 years are scarce, and the burden in children older than 5 years and in adults is also understudied. We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 to assess the burden of, and trends in, diarrhoeal diseases overall and attributable to 13 pathogens, as well as the contributions of associated risk factors, in children and adults in 204 countries and territories from 1990 to 2021.
View Article and Find Full Text PDFA consensus platform for antibody characterization.
Nat Protoc
December 2024
Department of Neurology and Neurosurgery, Structural Genomics Consortium, the Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Antibody-based research applications are critical for biological discovery. Yet there are no industry standards for comparing the performance of antibodies in various applications. We describe a knockout cell line-based antibody characterization platform, developed and approved jointly by industry and academic researchers, that enables the systematic comparison of antibody performance in western blot, immunoprecipitation and immunofluorescence.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!